期刊文献+

原发性胆汁性肝硬化25例分析

Clinical Study of 25 Primary Biliary Cirrhosis Cases
暂未订购
导出
摘要 目的:提高对原发性胆汁性肝硬化(PBC)的认识,总结PBC的诊治经验。方法:分析25例PBC患者的一般资料、临床特征、生化指标、免疫学异常及病理学改变。结果:PBC是肝内胆管进行性破坏并以慢性胆汁淤积为主要特征的不明原因的疾病,中年女性多见,易并干燥综合征(SS)。胆管酶升高及抗线粒体抗体M2型阳性、肝脏病理活检有助于本病诊断。治疗首选熊去氧胆酸,皮质类固醇激素、免疫抑制剂对部分病例有效。结论:早期诊断、治疗是防止PBC发展为终末期肝硬化的关键。 Objective: To enhance the recognition of primary biliary cirrhosis(PBC). Methods: 25 cases of primary biliary cirrhosis(PBC) were analyzed in clinical manifestations, biochemical indicators, immunological and pathological changes. Results: PBC mainly involved middle - age females and might combine with Sjoegren's Syndrome(SS). The raised hepatic enzymes , positive of anti- M2 antibody and pathological changes of liver conduced to the diagnosis of PBC. Ursodeoxycholic acid was the first selected drug for the treatment of PBC. Corticosteroid hormone and/or immunosuppressive agent were also available for some cases. Conclusions: Early diagnosis and treatment are the key points to prevent PBC from final stage cirrhosis.
出处 《现代临床医学》 2006年第4期261-263,共3页 Journal of Modern Clinical Medicine
关键词 肝硬化 胆汁性 诊断 治疗 cirrhosis biliary diagnosis treatment
  • 相关文献

参考文献5

  • 1Neuberger J. Primary biliary cirrhosis[ J]. Lancet,1997, 350(9081) :875 - 879.
  • 2O' Donohue J, Williams R. Primary biliary cirrhosis [ J ]. Q J M, 1996, 89(1):5-13.
  • 3Bach N, Odin JA. Primary biliary cirrhosis: a Mount Sinai Perspective. Mt Sinai J Med, 2003, 70:242 -250.
  • 4Talwalkar JA, Lindor KD. Primary biliary cirrhosis[J]. Lancet, 2003, 262(9377) :53 - 61.
  • 5张烜,唐福林.原发性胆汁性肝硬化临床诊治的认识[J].中华风湿病学杂志,2004,8(6):324-326. 被引量:5

二级参考文献16

  • 1Bandin O, Courvalin JC, Poupon R, et al. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology, 1996, 23: 1020-1024.
  • 2Bach N, Odin JA. Primary biliary cirrhosis: a Mount Sinai perspective. Mt Sinai J Med, 2003, 70: 242-250.
  • 3Kamihira T, Shimoda S, Harada K, et al. Distinct costimulation dependent and independent autoreactive T-cell clones in primary biliary cirrhosis. Gastroenterology, 2003, 125: 1379-1387.
  • 4Mitchison HC, Palmer JM, Bassendine MF, et al. A controlled trial of prednisolone treatment in primary biliary cirrhosis: threeyear results. J Hepatol, 1992, 15: 336-344.
  • 5Leuschner M, Guldutuna S, You T, et al. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol,1996, 25: 49-57.
  • 6Chan CW, Papatheodoridis GV, Goulis J, et al. Ursodeoxycholic acid and histological progression in primary biliary cirrhosis. J Hepatol, 2003, 39: 1094-1095.
  • 7Talwalkar JA, Lindor KD. Primary biliary cirrhosis. Lancet, 2003,262: 53-61.
  • 8Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol, 2003, 98: 431-437.
  • 9Ikuno N, Mackay IR, Jois J, et al. Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis.J Gastroenterol Hepatol, 2001, t6: 1390-1394.
  • 10Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet, 1996, 348: 1399-1402.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部